No Data
No Data
No Data
No Data
No Data
EV Biologics Completes Production of Cutting-Edge MSC Exosome-Based Therapeutic
TAMPA, FL / ACCESSWIRE / August 16, 2023 / EV Biologics Corp, OTC PINK:YECO, today announced that it has completed production of a next-generation, "Gen-2", MSC exosome-based therapeutic product.Rigorous
AccesswireAug 16, 2023 21:30
EV Biologics Launches Excyte With $100M Valuation
EV Biologics (OTCPK:YECO) is trading 41% higher after it said on Monday it had launched a subsidiary Excyte, Inc, with $100M valuation. The company said Excyte had already raised $500,000 of its $2.5M
Seeking AlphaAug 16, 2022 03:53
EV Biologics Launches Excyte With $100 Million Valuation
TAMPA, FL / ACCESSWIRE / August 15, 2022 / EV Biologics Corp, OTC Pink: YECO, today announced that it has launched Excyte, Inc., a wholly owned subsidiary, with $100 Million valuation.Excyte has alrea
AccesswireAug 15, 2022 21:05
EV Biologics Signs MSA with LONZA Cell & Gene Therapy
HOUSTON, TX / ACCESSWIRE / May 17, 2022 / EV Biologics Corp, OTC PINK:YECO, today announced that it has signed a Manufacturing Services Agreement (MSA) with Lonza for development of stem/progenitor ce
AccesswireMay 18, 2022 00:09
EV Biologics Isolates Primary Cells for Nanoparticle Production & Accelerated Cell Line Development
TAMPA, FL / ACCESSWIRE / April 12, 2022 / EV Biologics Corp, OTC PINK:YECO, today announced that it has succeeded in isolating primary progenitor cells from tissue using a xeno-free process.The Compan
AccesswireApr 12, 2022 21:06
EV Biologics Signs Listing Agreement With INX
Published: 11/11/2021 YECO NASHVILLE, TN / ACCESSWIRE / November 11, 2021 / EV Biologics Corp, (\"the Company\"), OTC PINK:YECO, today confirmed that it has signed an agreement to list its com
accesswireNov 12, 2021 10:32
No Data
No Data